Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

lek pharmaceuticals d.d. - lyophilized bacterial lysate - capsules hard - 3,5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

vertex pharmaceuticals (uk - ivacaftor - tablet - 150mg

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - ivacaftor 150mg;  ;  ; tezacaftor 100mg;  ;  ; ivacaftor 150mg - film coated tablet - active: ivacaftor 150mg     tezacaftor 100mg     excipient: croscarmellose sodium hypromellose hypromellose acetate succinate magnesium stearate microcrystalline cellulose opadry yellow 20a120010 sodium laurilsulfate active: ivacaftor 150mg excipient: carnauba wax colloidal silicon dioxide croscarmellose sodium hypromellose acetate succinate lactose monohydrate magnesium stearate microcrystalline cellulose opacode black s-1-17823 opadry blue 85f90614 sodium laurilsulfate - symdeko is indicated for the treatment of patients with cystic fibrosis (cf) aged 12 years and older who are homozygous for the f508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - elexacaftor 100mg;  ; ivacaftor 75mg;  ;  ; tezacaftor 50mg;  ;  ; ivacaftor 150mg - film coated tablet - active: elexacaftor 100mg   ivacaftor 75mg     tezacaftor 50mg     excipient: croscarmellose sodium hypromellose hypromellose acetate succinate magnesium stearate microcrystalline cellulose opadry orange 20a130039 sodium laurilsulfate active: ivacaftor 150mg excipient: carnauba wax colloidal silicon dioxide croscarmellose sodium hypromellose acetate succinate lactose monohydrate magnesium stearate microcrystalline cellulose opacode black s-1-17823 opadry blue 85f90614 sodium laurilsulfate - trikafta is indicated for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - elexacaftor 50mg;  ; ivacaftor 37.5mg;  ;  ; tezacaftor 25mg;  ;  ; ivacaftor 75mg - film coated tablet - active: elexacaftor 50mg   ivacaftor 37.5mg     tezacaftor 25mg     excipient: croscarmellose sodium hypromellose hypromellose acetate succinate magnesium stearate microcrystalline cellulose opadry orange 20a130039 sodium laurilsulfate active: ivacaftor 75mg excipient: carnauba wax colloidal silicon dioxide croscarmellose sodium hypromellose acetate succinate lactose monohydrate magnesium stearate microcrystalline cellulose opacode black s-1-17823 opadry blue 85f105098 sodium laurilsulfate - trikafta is indicated for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.